ADVERTISEMENT

404

Not Found

Is this what you were looking for?

tag big pharma ecology disease medicine cell molecular biology

bacteria and DNA molecules on a purple background.
Engineering the Microbiome: CRISPR Leads the Way
Mariella Bodemeier Loayza Careaga, PhD | Mar 15, 2024 | 10+ min read
Scientists have genetically modified isolated microbes for decades. Now, using CRISPR, they intend to target entire microbiomes.
A rendering of a human brain in blue on a dark background with blue and white lines surrounding the brain to represent the construction of new connections in the brain.
Defying Dogma: Decentralized Translation in Neurons
Danielle Gerhard, PhD | Sep 8, 2023 | 10+ min read
To understand how memories are formed and maintained, neuroscientists travel far beyond the cell body in search of answers.
Pharma Looks to Inflammasome Inhibitors as All-Around Therapies
Rachael Moeller Gorman | Apr 1, 2021 | 10+ min read
Many major biopharmaceutical companies are developing or acquiring drugs that target the NLRP3 inflammasome, a large intracellular complex that researchers say can spark inflammation and stoke diseases of lifestyle and aging.
Researchers in George Church&rsquo;s lab modified wild type ADK proteins (left) in <em >E.coli</em>, furnishing them with an nonstandard amino acid (nsAA) meant to biocontain the resulting bacterial strain.
A Pioneer of The Multiplex Frontier
Rashmi Shivni, Drug Discovery News | May 20, 2023 | 10 min read
George Church is at it again, this time using multiplex gene editing to create virus-proof cells, improve organ transplant success, and protect elephants.
Weathering Hantavirus: Ecological Monitoring Provides Predictive Model
Steve Bunk | Jul 4, 1999 | 7 min read
Photo: Steve Bunk Dave Tinnin, field research associate in the University of New Mexico's biology department, takes blood samples and measurements of rodents caught on the research station grounds. At the end of a freeway exit near Soccoro, N.M., the hairpin turn onto a gravel road is marked by a sign that warns, "Wrong Way." But it isn't the wrong way if you want to reach the University of New Mexico's (UNM) long-term ecological research (LTER) station. The sign's subterfuge is the first indi
Computational Biology: Growing Field Melds Big Computers And Life Sciences
Franklin Hoke | Dec 6, 1992 | 8 min read
Sciences Date: December 7, 1992 The energetic young field of computational biology is looking to the coming generation of massively parallel computers for its future, researchers say. These machines, enhanced by the contributions of computer scientists who are developing innovative programming tactics, will be crucial in allowing biological researchers to reach ambitious goals. "Parallel computers are going to let this field take off," says Andrew McCammon, a theoretical chemist at the Unive
Scientific Community Recognizing Link Between Ecology And Health
Karen Young Kreeger | Mar 3, 1996 | 9 min read
SENSE OF PROPORTION: "more needs to be done relative to the scale of the problem," remarks Stanford ecologist Gretchen Daily. The worldwide spate of emerging and reemerging infectious diseases in the first half of this decade has prompted a growing recognition of the connection between global climate change and human health. Individual researchers from such disparate disciplines as epidemiology and public health, ecology, virology, climatology, nutrition, and biomedicine have directly addresse
Monoclonal Antibodies Find Utility In Cell Biology
Ricki Lewis | Dec 11, 1994 | 10+ min read
But, just as antibodies are finding increasing utility in cell biology, a new Food and Drug Administration classification for those products with clinical utility may affect researchers' access to the important technology (see accompanying story). Monoclonal History MAbs were born in 1975, when Georges Kohler and Cesar Milstein at the Medical Research Council Laboratories in Cambridge, England, fused two types of cells to form a hy
Monoclonal Antibodies Find Utility In Cell Biology
Ricki Lewis | Dec 11, 1994 | 10+ min read
But, just as antibodies are finding increasing utility in cell biology, a new Food and Drug Administration classification for those products with clinical utility may affect researchers' access to the important technology (see accompanying story). Monoclonal History MAbs were born in 1975, when Georges Kohler and Cesar Milstein at the Medical Research Council Laboratories in Cambridge, England, fused two types of cells to form a hy
Guts and Glory
Anna Azvolinsky | Apr 1, 2016 | 9 min read
An open mind and collaborative spirit have taken Hans Clevers on a journey from medicine to developmental biology, gastroenterology, cancer, and stem cells.

Run a Search

ADVERTISEMENT